U.S. drug developer Capricor places Duchenne drug trial on hold
(Reuters) – Capricor Therapeutics Inc said on Wednesday it had put on hold a clinical trial of its drug to treat Duchenne muscular dystrophy (DMD), a muscle-wasting disorder, citing a safety review. The review follows a severe allergic reaction during infusion of the drug, the company said in a filing here. The patient responded well… Read More »